Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Novo Nordisk A/S Class B (0QIU)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
893.05 +18.90    +2.16%
11:35:59 - Closed. Currency in DKK ( Disclaimer )
Type:  Equity
Market:  United Kingdom
ISIN:  DK0060534915 
SEDOL:  BP6KMR9
  • Volume: 143,394
  • Bid/Ask: 855.50 / 890.40
  • Day's Range: 878.10 - 893.70
Novo Nordisk B 893.05 +18.90 +2.16%

0QIU Ratios

 
Assess the performance of Novo Nordisk B (NOVOb). This table contains core financial ratios such as Price-to-Earnings (P/E ratio), Return-On-Investment (ROI), Earnings per share (EPS), Dividend yield and others based on Novo Nordisk A/S Class B's latest financial reports. Compare the performance metrics of Novo Nordisk B (NOVOb) against the industry averages.
InvestingPro Advanced Ratios
Name Company Industry
   
P/E Ratio TTM 46.66 76.03
Price to Sales TTM 16.81 10.36
Price to Cash Flow MRQ 35.86 32.69
Price to Free Cash Flow TTM 46.99 47.78
Price to Book MRQ 36.65 22.81
Price to Tangible Book MRQ 86.28 94.09
   
Profitability: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Gross margin TTM 84.6% 76.39
Gross Margin 5YA 83.81% 74.27
Operating margin TTM 44.77% 32.63
Operating margin 5YA 43.03% 31.25
Pretax margin TTM 45.07% 27.36
Pretax margin 5YA 41.25% 27.31
Net Profit margin TTM 36.03% 22.37
Net Profit margin 5YA 33.1% 23.02
   
Revenue/Share TTM 52.1 1,051.36
Basic EPS ANN 18.67 201.23
Diluted EPS ANN 18.62 201.2
Book Value/Share MRQ 23.9 1,350.81
Tangible Book Value/Share MRQ 10.35 1,007.44
Cash/Share MRQ 3.23 123.8
Cash Flow/Share TTM 24.43 193.46
   
Management Effectiveness: TTM vs 5 Year Average Margins
 TTM (%)
 5 Year Avg. (%)
Return on Equity TTM 88.07% 50.69
Return on Equity 5YA 76.6% 52.52
Return on Assets TTM 30.12% 17.7
Return on Assets 5YA 30.33% 19.38
Return on Investment TTM 68.52% 40.35
Return on Investment 5YA 67.92% 40.4
   
EPS(MRQ) vs Qtr. 1 Yr. Ago MRQ 63.15% 9.15
EPS(TTM) vs TTM 1 Yr. Ago TTM 52.32% 9.4
5 Year EPS Growth 5YA 18.52% 26.07
Sales (MRQ) vs Qtr. 1 Yr. Ago MRQ 36.95% 16.46
Sales (TTM) vs TTM 1 Yr. Ago TTM 31.26% 18.48
5 Year Sales Growth 5YA 15.74% 12.76
5 Year Capital Spending Growth 5YA 21.78% 14.28
   
Quick Ratio MRQ 0.56 0.96
Current Ratio MRQ 0.82 1.4
LT Debt to Equity MRQ 14.99% 49.98
Total Debt to Equity MRQ 25.34% 61.07
Efficiency    
Asset Turnover TTM 0.84 0.61
Inventory Turnover TTM 1.27 1.65
Revenue/Employee TTM 3.67M 17.30M
Net Income/Employee TTM 1.32M 2.20M
Receivable Turnover TTM 4.49 3.66
   
Dividend Yield ANN 1.02% 1.87
Dividend Yield 5 Year Avg. 5YA 1.76% 2.26
Dividend Growth Rate ANN 68.61% 15.51
Payout Ratio TTM 37.96% 44.42
TTM = Trailing Twelve Months  5YA = 5-Year Average  MRQ = Most Recent Quarter
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced valuation and financial ratios for in-depth analysis of company financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NOVOb Comments

Write your thoughts about Novo Nordisk L
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
HH HH
HH HH Jun 12, 2023 8:33AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
My investment propensity test was surprising that Jim Simon, a Renaissance technology, had the most stocks he owned, but it was even more surprising that Novo Nordisk AS. Because it was the only event I recommended to my friend. HHH
Terrible Investor
TerribleInvestor Apr 13, 2023 7:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Boooooom! 30%.
Terrible Investor
TerribleInvestor Jan 03, 2023 11:59PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Very very bullish!
Terrible Investor
TerribleInvestor Jan 03, 2023 11:59PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Those dislikes didnt age well
Karsten Vester
Karsten Vester Jan 03, 2023 11:59PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Dislikes dont know anything obviously
Toby Brunt
Toby Brunt Apr 19, 2022 5:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Does anyone no of a particular reason that NOVO B is going so far down today? Is it profit taking before Q1 2022 results?
HH HH
HH HH Apr 19, 2022 5:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I used to do the same thing. In the case of novice investment, we try to find out the reason for the fall and rise in stock prices. It's a futile act. The rise and fall in stock prices are just for Manipulators to move in a predetermined scenario. So a successful investment is a quick insight into Manipulators' scenarios. HHH
Sandy SS
Sandy SS Feb 09, 2022 8:36AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
New Target 825 by EOM
Sandy SS
Sandy SS Feb 09, 2022 8:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
New Target 825
Terrible Investor
TerribleInvestor Nov 25, 2021 5:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Consolidating nicely for leg up to 850!🌟
Ralf Adams
Ralf Adams Feb 11, 2021 4:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Results from clinical study just published in New England Journal of Medicine: Impressive new weight loss results for Semaglutide at only 2.4 mg once a week. Drug mimics the gut hormone glucagon-like peptide-1 (GLP-1) that is secreted by your gut after eating.
Candy Man
Candy Man Jan 14, 2021 4:16PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Now is the time to buy - novo is very seasonal stock goes up the most in jan/feb.
Carlos Andres
Carlos Andres Aug 25, 2020 4:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bullish??
Carlos Andres
Carlos Andres Aug 25, 2020 4:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
No. Funds are selling. Time to wait to go long...
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email